Tongue squamous cell carcinoma

Summary

Tongue squamous cell carcinoma (MONDO:0000500) is a cancer and 8 clinical trials. Top therapeutic interventions include fludeoxyglucose f 18. A subtype of tongue cancer — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 8

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	tongue squamous cell carcinoma
Mondo ID	MONDO:0000500
DOID	DOID:0050865
NCIT	C4648
SNOMED CT	276952000
UMLS	C0349566
MedGen	91153
GARD	0022779
Anatomy (UBERON)	UBERON:0001723
Is cancer (heuristic)	yes

Also known as: scc of the tongue · scc of tongue · squamous cell carcinoma of the tongue · squamous cell carcinoma of tongue · tongue scc · tongue squamous cell carcinoma

Data availability: 293 cell lines.

Disease family

This is a subtype of tongue cancer. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › nervous system cancer › sensory system cancer › tongue cancer › tongue squamous cell carcinoma

Related subtypes (1): tongue carcinoma

Subtypes (1): squamous cell carcinoma of the oral tongue

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 8.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	5
PHASE2/PHASE3	1
PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04333537	PHASE2/PHASE3	RECRUITING	Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer
NCT07346807	PHASE2	NOT_YET_RECRUITING	Lingual Nerve Disruption to Augment Neoadjuvant Chemoimmunotherapy in Locally Advanced Tongue Cancer
NCT07217171	PHASE1	RECRUITING	A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
NCT07466810	Not specified	NOT_YET_RECRUITING	Resection and Defect Repair of Oral Cancer Aided by Mixed Reality Technology
NCT03440151	Not specified	UNKNOWN	Oncological Outcome of Contralateral Submental Artery Island Flap Versus Primary Closure in Tongue Squamous Cell Carcinoma
NCT04614896	Not specified	COMPLETED	Use of Ultrasound for Measuring Size of Oral Tongue Cancers
NCT05424328	Not specified	WITHDRAWN	Virtual Planning of ALT Flap
NCT05843032	Not specified	UNKNOWN	3D Ultrasound, Specimen Examination by Surgeon, and MRI in Surgical Margin Assessment

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
FLUDEOXYGLUCOSE F 18	4	1